Longwood-Founded Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform Business Wire: November 21, 2019 Read More
Go back to Press Page
